Home » Stocks » AVTE

Aerovate Therapeutics, Inc. (AVTE)

Aerovate Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) -10.96M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

News

Aerovate Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

1 week ago - SEC

About AVTE

Aerovate Therapeutics is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Our initial focus is on advancing AV-101, our dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, or PAH, a devastating disease impacting approximately 70,000 people in the United States and Europe. Imatinib, marketed as Gleevec tablets, was originally developed for the treatment of multiple cancers. Oral imatinib also demon... [Read more...]

Industry
Pharmaceutical Preparations
IPO Date
Pending
CEO
Timothy P. Noyes
Employees
7
Stock Exchange
NASDAQ
Ticker Symbol
AVTE
Full Company Profile

Financial Performance

Financial Statements